GlassScriptPhysician profile
Michael Vincent Patrone
NPI 1134619992
$445.45
in general payments reported to CMS, 2019-2025
12 companies · $307 in 2025
The $307 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $12.15 · 2024: $126 · 2025: $307.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $353 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $353.31 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $103.33 | 2025 | |
| Janssen Biotech, INC. | $79.99 | 2024 | Stelara |
| Enterra Medical, INC. | $36.07 | 2025 | |
| Ardelyx, INC. | $35.15 | 2025 | Ibsrela |
| Boston Scientific Corporation | $32.15 | 2022-2024 | Compliance Endokit |
| Madrigal Pharmaceuticals | $30.76 | 2025 | Rezdiffra |
| Merit Medical Systems INC | $27.24 | 2024-2025 | Alimaxx-Esophageal Stent/Delivery System, Endomaxx Stent and Delivery System |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.57 | 2025 | Xifaxan |
| Genzyme Corporation | $24.39 | 2025 | |
| Phathom Pharmaceuticals, INC. | $20.26 | 2025 | Voquezna |
| Pfizer INC. | $16.39 | 2025 | |
| Conmed Corporation | $15.15 | 2024 | Conmed Biliary, Conmed Dilation, Conmed Generators |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Patrone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.